Tempest regains Nasdaq minimum bid price compliance

Tempest Therapeutics, Inc.

Received formal Nasdaq notification on Oct 26, 2023, confirming compliance with Listing Rule 5450(a)(1).
Rule requires closing bid price of at least $1.00 per share for continued listing.
Regaining compliance removes potential delisting risk for TPST common stock.

item 8.01

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-265621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.